Payment overview · 2025
General Payments
$3,351.97
223 reported records · 27 companies
Healthcare provider profile · identity verified
Daniel Polansky, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1578561593
Verified facts
What the public records show
CMS Open Payments records show Daniel Polansky, MD received $3,351.97 in general payments during 2025 across 223 reported records.
ABBVIE INC. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Mounjaro, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Xarelto by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $850.11 | 25.4% | 68 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $504.20 | 15.0% | 31 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $340.03 | 10.1% | 24 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $302.50 | 9.0% | 16 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $190.62 | 5.7% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $187.98 | 5.6% | 17 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $185.73 | 5.5% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $118.35 | 3.5% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $70.79 | 2.1% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $65.16 | 1.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.48 | 1.8% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $54.58 | 1.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.91 | 1.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.11 | 1.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.72 | 1.4% | 4 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $39.59 | 1.2% | 2 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $36.01 | 1.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.64 | 1.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $31.55 | 0.9% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.68 | 0.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.45 | 0.6% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $19.19 | 0.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.41 | 0.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.29 | 0.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.26 | 0.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.36 | 0.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.27 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,351.97 | 223 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $283.40 | 23 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $283.03 | 23 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $281.75 | 15 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $246.51 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $235.57 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $223.64 | 15 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $206.15 | 22 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $190.62 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $185.73 | 15 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $134.93 | 7 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $130.75 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $118.60 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $118.35 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $118.35 | 5 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $114.45 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $110.78 | 11 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $107.64 | 11 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $107.64 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $107.29 | 10 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $97.81 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $92.23 | 8 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc | $84.61 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $80.34 | 6 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $70.79 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $61.48 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $54.58 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.91 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $46.11 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.72 | 4 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $39.59 | 2 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $36.01 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| Cimzia Normalized: cimzia |
Drug | UCB, Inc. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $9.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 59 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 218 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 175 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 98 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
98 | 18 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
125 | 22 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
125 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
218 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
175 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
278 | 59 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 787 | 242 |
| Amlodipine Besylate | Amlodipine Besylate | 621 | 204 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 557 | 178 |
| Gabapentin | Gabapentin | 526 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 525 | 141 |
| Pantoprazole Sodium | Pantoprazole Sodium | 509 | 171 |
| Promethazine Hcl | Promethazine Hcl | 506 | 76 |
| Tizanidine Hcl | Tizanidine Hcl | 493 | 106 |
| Omeprazole | Omeprazole | 475 | 148 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 404 | 106 |
| Furosemide | Furosemide | 379 | 120 |
| Tramadol Hcl | Tramadol Hcl | 349 | 100 |
| Meloxicam | Meloxicam | 335 | 95 |
| Alprazolam | Alprazolam | 284 | 43 |
| Eliquis | Apixaban | 278 | 59 |
| Metformin Hcl | Metformin Hcl | 276 | 79 |
| Potassium Chloride | Potassium Chloride | 274 | 88 |
| Carvedilol | Carvedilol | 249 | 90 |
| Zolpidem Tartrate | Zolpidem Tartrate | 239 | 37 |
| Azithromycin | Azithromycin | 228 | 153 |
| Diazepam | Diazepam | 228 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 70 |
| Losartan Potassium | Losartan Potassium | 224 | 71 |
| Lisinopril | Lisinopril | 223 | 65 |
| Clonidine Hcl | Clonidine Hcl | 222 | 68 |
| Ibuprofen | Ibuprofen | 220 | 79 |
| Mounjaro | Tirzepatide | 218 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 76 |
| Pregabalin | Pregabalin | 213 | 49 |
| Trazodone Hcl | Trazodone Hcl | 213 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 69 |
| Allopurinol | Allopurinol | 195 | 57 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 194 | 58 |
| Clonazepam | Clonazepam | 180 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 176 | 51 |
| Ozempic | Semaglutide | 175 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 170 | 50 |
| Simvastatin | Simvastatin | 169 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 165 | 54 |
| Ondansetron Hcl | Ondansetron Hcl | 159 | 62 |
| Metformin Hcl Er | Metformin Hcl | 149 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 131 | 29 |
| Xarelto | Rivaroxaban | 125 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 41 |
| Methylprednisolone | Methylprednisolone | 124 | 94 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 41 |
| Celecoxib | Celecoxib | 122 | 33 |
| Prednisone | Prednisone | 122 | 67 |
| Jardiance | Empagliflozin | 119 | 25 |
| Fluconazole | Fluconazole | 113 | 66 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 31 |
| Lorazepam | Lorazepam | 111 | 21 |
| Cefuroxime | Cefuroxime Axetil | 110 | 80 |
| Buspirone Hcl | Buspirone Hcl | 107 | 32 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 107 | 76 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 103 | 19 |
| Montelukast Sodium | Montelukast Sodium | 103 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 100 | 83 |
| Methocarbamol | Methocarbamol | 98 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 26 |
| Atenolol | Atenolol | 96 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 30 |
| Amoxicillin | Amoxicillin | 94 | 44 |
| Methadone Hcl | Methadone Hcl | 94 | 18 |
| Sertraline Hcl | Sertraline Hcl | 94 | 27 |
| Cephalexin | Cephalexin | 93 | 69 |
| Spironolactone | Spironolactone | 90 | 26 |
| Meclizine Hcl | Meclizine Hcl | 88 | 30 |
| Mirtazapine | Mirtazapine | 88 | 23 |
| Famotidine | Famotidine | 87 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 29 |
| Naproxen | Naproxen | 87 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 84 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 84 | 28 |
| Dicyclomine Hcl | Dicyclomine Hcl | 82 | 26 |
| Farxiga | Dapagliflozin Propanediol | 79 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 79 | 22 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 77 | 19 |
| Donepezil Hcl | Donepezil Hcl | 72 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 18 |
| Colchicine | Colchicine | 66 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 54 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 15 |
| Eszopiclone | Eszopiclone | 62 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 62 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 51 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 60 | 27 |
| Linzess | Linaclotide | 59 | 22 |
| Doxepin Hcl | Doxepin Hcl | 58 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 57 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 46 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 18 |
| Baclofen | Baclofen | 55 | 21 |
| Januvia | Sitagliptin Phosphate | 55 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 31 |
| Glimepiride | Glimepiride | 54 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | suppressed |
| Flurbiprofen | Flurbiprofen | 52 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | 15 |
| Ondansetron Odt | Ondansetron | 51 | 20 |
| Synthroid | Levothyroxine Sodium | 51 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 50 | 16 |
| Bupropion Xl | Bupropion Hcl | 50 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 15 |
| Sucralfate | Sucralfate | 49 | 19 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 16 |
| Estradiol | Estradiol | 48 | 14 |
| Lidocaine | Lidocaine | 48 | 20 |
| Nitroglycerin | Nitroglycerin | 48 | 24 |
| Nortriptyline Hcl | Nortriptyline Hcl | 48 | suppressed |
| Torsemide | Torsemide | 48 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 11 |
| Memantine Hcl | Memantine Hcl | 46 | 14 |
| Nabumetone | Nabumetone | 45 | suppressed |
| Nystatin | Nystatin | 45 | 28 |
| Indapamide | Indapamide | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | 13 |
| Glipizide Er | Glipizide | 42 | 12 |
| Hydrocortisone | Hydrocortisone | 42 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 14 |
| Cefdinir | Cefdinir | 41 | 37 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | 15 |
| Olanzapine | Olanzapine | 41 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | 13 |
| Entresto | Sacubitril/Valsartan | 38 | 12 |
| Levetiracetam | Levetiracetam | 38 | 14 |
| Levofloxacin | Levofloxacin | 38 | 28 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Valsartan | Valsartan | 38 | 14 |
| Verapamil Er | Verapamil Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 16 |
| Midodrine Hcl | Midodrine Hcl | 37 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Lubiprostone | Lubiprostone | 35 | 13 |
| Glipizide | Glipizide | 34 | 12 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Nifedipine Er | Nifedipine | 34 | 11 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | 13 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 13 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 32 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 32 | 12 |
| Temazepam | Temazepam | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | suppressed |
| Perphenazine | Perphenazine | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 29 | 12 |
| Benazepril Hcl | Benazepril Hcl | 28 | 11 |
| Desloratadine | Desloratadine | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Lactulose | Lactulose | 28 | 14 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Finasteride | Finasteride | 27 | 11 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 27 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Armour Thyroid | Thyroid,pork | 25 | suppressed |
| Clarithromycin | Clarithromycin | 25 | 23 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 18 |
| Dexamethasone | Dexamethasone | 23 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Piroxicam | Piroxicam | 23 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 15 |
| Diclofenac Sodium Er | Diclofenac Sodium | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Indomethacin | Indomethacin | 20 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 20 | suppressed |
| Sulindac | Sulindac | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Nadolol | Nadolol | 19 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 13 |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Oxazepam | Oxazepam | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Acarbose | Acarbose | 16 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Misoprostol | Misoprostol | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Ambien Cr | Zolpidem Tartrate | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 13 | suppressed |
| Plavix | Clopidogrel Bisulfate | 13 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Kristalose | Lactulose | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Plaquenil | Hydroxychloroquine Sulfate | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,351.97 · 223 records | ABBVIE INC. | AREXVY, Auvelity, Bimzelx, CAPLYTA, CREON, Cimzia, ENBREL, EVENITY, FARXIGA, GEMTESA, IBSRELA, KEVZARA, Kerendia, Korlym, LINZESS, LUPKYNIS, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PEMGARDA, PROLIA, QULIPTA, REPATHA, REXULTI, RINVOQ, Rybelsus, SHINGRIX, SKYRIZI, TRELEGY ELLIPTA, TREMFYA, TRINTELLIX, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error